9 Meters Biopharma Provides Business Update and Reports Financial Results for the Fourth Quarter and Full Year 2020 tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.
To print this article, all you need is to be registered or login on Mondaq.com.
On March 9, 2021, Mayor Bill de Blasio announced a series of
proposed citywide zoning text amendments intended to incentivize
the creation of local grocery stores, boost transit station
accessibility, and ease administrative burdens for gyms and
restaurants. The proposed zoning changes are expected to enter the
city s public review process this spring or summer, which could
put them on track to be approved before the end of this year.
FRESH Program Updates
The Food Retail Expansion to Support Health (FRESH) program was
created in 2009 to encourage the construction of supermarkets in
Mayor de Blasio Proposes Zoning Changes Intended to Promote the City s Recovery | Kramer Levin Naftalis & Frankel LLP jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.
Poseida Therapeutics Reports Program Updates and Financial Results for the Fourth Quarter and Full Year 2020
News provided by
Share this article
Share this article
SAN DIEGO, March 11, 2021 /PRNewswire/ Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the fourth quarter and full year ended December 31, 2020. 2020 was a transformative year for Poseida, as we completed our IPO and became a public company all while advancing multiple programs and substantially expanding the application of our core technologies, enabling us to engineer a portfolio of product candidates designed to overcome the limitations of current cell and gene therapeutics, said Eric Ostertag, M.D., Ph.D., Chief Executive Officer of Poseida. This important progress was on display in lat
Share this article
LA JOLLA, Calif., March 9, 2021 /PRNewswire/
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the Company or Regulus ), today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update. Regulus finished the year on a high note , stated Jay Hagan, CEO of Regulus. We advanced RGLS4326 into a Phase 1b study in ADPKD patients, achieved an enrollment milestone for RG-012 with Sanofi and its Phase 2 clinical study for the treatment of patients with Alport syndrome, and completed a private financing. With the recent progress, we believe we are well positioned to advance the ADPKD program through Phase 1b while also advancing our next generation ADPKD compound toward the clinic.